Changes in Hong Kong stocks | Kingsley Biotech (01548) rose more than 13% in the afternoon. In the second quarter, CARVYKTI sales reached US$657 million, up nearly 50% year-on-year

The Zhitong Finance App learned that Kingsley Biotech (01548) rose more than 13% in the afternoon. As of press release, it had risen 11.66% to HK$16.37, with a turnover of HK$754 million.

According to the news, Kingsley Biotech recently announced that in the second quarter, legendary biological CARVYKTI's sales reached 657 million US dollars, up 49.4% year on year and 10% month on month. Sales for the first half of the year reached US$1,254 million, up 55.1% year over year. Annual sales are expected to exceed 2.5 billion US dollars. According to public information, up to now, CARVYKTI has treated more than 10,000 patients.

Notably, Trump announced a 100% tariff on generic drugs after two years. Analysts pointed out that the direct impact of the policy on innovative drugs may be limited, but it may force companies to lay out production capacity in the US ahead of schedule. According to reports, Johnson & Johnson and Legend Biotech have added commercial production bases in the US, New Jersey, and Ghent, Belgium, etc., and commissioned CMO and new internal production line planning. The annual production capacity of CARVYKTI is expected to expand exponentially from the current level in the next few years.